We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PINC
1976
DELISTED
Premier
PINC
$471K ﹤0.01%
14,405
-3,613
-20% -$119K
MBI icon
1977
MBIA
MBI
$262M
$470K ﹤0.01%
68,850
-15,700
-19% -$117K
RIGL icon
1978
Rigel Pharmaceuticals
RIGL
$762M
$469K ﹤0.01%
21,036
BRKL
1979
DELISTED
Brookline Bancorp
BRKL
$468K ﹤0.01%
42,399
BZH icon
1980
Beazer Homes USA
BZH
$874M
$467K ﹤0.01%
60,220
+11,900
+25% +$96.4K
TMP icon
1981
Tompkins Financial
TMP
$1.45B
$465K ﹤0.01%
7,151
NTK
1982
DELISTED
NORTEK INC COM NEW (DE)
NTK
$464K ﹤0.01%
7,820
+900
+13% +$44.2K
FNB icon
1983
FNB Corp
FNB
$6.88B
$462K ﹤0.01%
36,877
INDB icon
1984
Independent Bank
INDB
$4.05B
$462K ﹤0.01%
10,120
FFIC
1985
DELISTED
Flushing Financial
FFIC
$460K ﹤0.01%
23,162
+2,187
+10% +$44.7K
NXGN
1986
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
$460K ﹤0.01%
38,600
+5,500
+17% +$74K
SPNE
1987
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$460K ﹤0.01%
43,899
+2,200
+5% +$26.5K
FCEL icon
1988
FuelCell Energy
FCEL
$1.63B
$459K ﹤0.01%
205
+55
+37% +$126K
VRNT
1989
DELISTED
Verint Systems
VRNT
$459K ﹤0.01%
27,207
HT
1990
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
$458K ﹤0.01%
26,705
-1,100
-4% -$20.8K
ZNGA
1991
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
$458K ﹤0.01%
183,776
POT
1992
DELISTED
Potash Corp Of Saskatchewan
POT
$458K ﹤0.01%
28,300
-2,500
-8% -$41.8K
ITG
1993
DELISTED
Investment Technology Group Inc
ITG
$456K ﹤0.01%
27,300
BGC icon
1994
BGC Group
BGC
$5.2B
$455K ﹤0.01%
81,294
+278
+0.3% +$1.61K
ICON
1995
DELISTED
Iconix Brand Group, Inc.
ICON
$454K ﹤0.01%
6,715
+3,160
+89% +$246K
BCO icon
1996
Brink's
BCO
$4.72B
$450K ﹤0.01%
15,779
CVSA
1997
Covista Inc
CVSA
$4.49B
$449K ﹤0.01%
25,160
+5,400
+27% +$95.2K
MDRX
1998
DELISTED
Veradigm Inc. Common Stock
MDRX
$449K ﹤0.01%
35,390
SPNC
1999
DELISTED
Spectranetics Corp
SPNC
$449K ﹤0.01%
24,000
+6,400
+36% +$113K
MSGN
2000
DELISTED
MSG Networks Inc.
MSGN
$448K ﹤0.01%
29,200
+60
+0.2% +$1.01K

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.